4DMedical (Imbio)
Overview
4DMedical is a global medical technology company that provides advanced imaging software for respiratory diagnostics. Through its patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity. The company’s solutions, including FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and Computed Tomography-enabled counterpart software (CT LVAS™), deliver quantitative lung ventilation data. In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. This acquisition expanded 4DMedical’s portfolio to include AI-driven diagnostic tools that provide comprehensive cardiothoracic analysis from standard CT scans.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Quantitative lung ventilation analysis (XV LVASu00ae, CT LVASu2122)
- Non-contrast ventilation-perfusion mapping (CT:VQu2122)
- Coronary Artery Calcification (CACu2122) quantification
- Early IPF Detection (IQ-UIPu2122)
- Functional Lung Density Analysis (LDAfu2122)
- Lung Density Analysis u2013 Inspiration (LDAiu2122) for emphysema assessment
- Lung Texture Analysis (LTAu2122) for interstitial lung disease assessment
- Pulmonary Hypertension Assessment (PHAu2122)
- Automated airway measurement
- Cloud-based Software-as-a-Service (SaaS) delivery model
Use Cases
- Early detection and diagnosis of respiratory deficiencies
- Monitoring changes in lung function over time
- Assessment of emphysema and COPD
- Support for lung cancer screening programs
- Pulmonary embolism workups and CTEPH assessment
- Surgical planning and pulmonary vascular disease assessment
What Physicians Need to Know
For radiologists and cardiologists, 4DMedical (Imbio)'s CACu2122 tool can be invaluable for efficiently assessing coronary artery calcification from existing non-contrast chest CT scans, streamlining the evaluation of patients with dyspnea and aiding in distinguishing between cardiac and pulmonary causes. The automated RV/LV Analysisu2122 provides crucial quantitative data on right ventricular dilation, which can assist in risk stratification for pulmonary conditions like pulmonary embolism, potentially saving reporting time and standardizing reporting of right heart strain. These tools can provide objective, reproducible quantification and visualization, enhancing diagnostic accuracy and guiding referrals.
4DMedical (Imbio) solutions are designed for integration into clinical workflows. The CACu2122 software results are directly routed to PACS for immediate review and integration. Imbio's products, including Lung Density Analysis (LDA) and RV/LV Analysis, are available through global partners and can be integrated into radiology reporting workflows via platforms like the Nuance AI Marketplace and PowerShare Network. 4DMedical has also partnered with Blackford Analysis Inc. to distribute Imbio's medical imaging AI solutions through the Blackford Platformu2122, which is an AI marketplace that consolidates disparate AI clinical applications and provides access through integration, workflow, orchestration, and reporting. Imbio's Core Computing Platform (CCP) offers both cloud and on-premise hosted options for running computationally-intensive image algorithms, integrating with native DICOM tools and workflows.
Details
| Category | Cardiology AI, Radiology & Imaging AI |
| Pricing | Unknown — unknown |
| Deployment | Cloud (Imbio Cloud in AWS) or On-premise (Imbio Enterprise) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Unknown AI-estimated 4DMedical's XV Technology® is FDA cleared. Imbio's products, including Lung Density Analysis™ and RV/LV Analysis™, also have FDA 510(k) clearance. Most recently, 4DMedical received FDA 510(k) clearance for CT:VQ, a technology that converts standard non-contrast chest CT scans into quantitative ventilation and perfusion maps. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Pulmonology, Radiology |
What the Web Says
4DMedical (Imbio) provides AI-powered medical imaging solutions for chronic lung and cardiothoracic diseases, aiming to transform patient diagnosis, treatment, and management. Physicians highlight its ability to turn standard medical imaging into personalized medicine, offering quantitative analysis and visualization that can aid in surgical eligibility assessment, treatment decisions, and patient communication. The company's solutions are designed to be fully automated and integrate into existing hospital workflows, providing rapid analysis and reports.
Overall: PositiveStrengths
- Automated and effortless integration into existing radiology workflows.
- Provides quantitative and personalized imaging analysis for acute and chronic conditions.
- Enhances detection and monitoring of various lung diseases (e.g., COPD, fibrosis, lung cancer).
- Aids in assessing surgical eligibility, facilitating informed decision-making, and improving patient communication.
- Can help identify undiagnosed patients with lung conditions, leading to earlier intervention.
- Offers actionable cardiovascular risk data from non-contrast chest CTs.
Limitations
- Some Reddit users express concerns about the company's valuation relative to its revenue in early stages.
- Sales representatives may lack in-depth technical knowledge of the product.
- Potential challenges in getting medical teams to adopt new automated processes over established manual habits.
- The software is not intended as a primary tool for disease detection and/or diagnosis, and clinicians are responsible for final determinations.
- One Reddit user noted that the product seemed to work as advertised, but sales representatives were seeking insight on utilization rather than actively selling.
Based on reviews from: 4DMedical.com - Case Studies - Imbio, 4DMedical Limited - Owning the lung - ASX, Nuance AI Marketplace - Imbio lung AI models support lung disease diagnosis and care, Blackford Analysis - Imbio - Quantitative reports for chest CT scans, Imbio - Helping the population breathe with patient-centered AI solutions, IMBIO'S CT LUNG ANALYSIS SOFTWARE RECEIVES 510(K) CLEARANCE FROM FDA, 4DMedical.com - FAQs - Imbio, Becker's Hospital Review - NTT Data, Imbio collaborate on personalized lung care, AP News - Imbio Receives FDA 510(k) Clearance for New Cardiothoracic Imaging Algorithm, 4DMedical.com - CASE STUDY (University of Chicago), Reddit - r/ASX - What do you guys think of 4DMEDICAL?, Reddit - r/4DMedical, PR Newswire - 4DMedical and Imbio Merge to Create Comprehensive Cardiothoracic Image Analysis Portfolio, PR Newswire - Imbio Partners with Siemens Healthineers to Deliver Image Analysis Tools to Clinicians Across the Globe, 4DMedical.com - IMBIO IQ-UIP USER MANUAL, GuruFocus - Imbio to be Acquired by 4DMedical Creating Comprehensive Cardiot, 4DMedical.com - Deployment Options - Imbio, Reddit - r/ASX - 4d Medical - Andreas Fouras, Respiratory Therapy - 4DMedical to Acquire Imbio to Bolster Lung Imaging Tech, Reddit - r/4DMedical, PR Newswire - Imbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio, PR Newswire - 4DMedical Receives TGA Approval for CT:VQu2122, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia, Reddit - r/Radiology - Has anyone heard of 4DX Medical for Non Contrast Vent + Perf Scans?, 4DMedical.com - CAC, Indeed.com - 4DMedical Interview Questions & Answers, Listcorp - Investor Presentation Imbio acquisition and capital raise - 4DMedical Limited (ASX:4DX), Capterra - Unlimited Financials Reviews 2026. Verified Reviews, Pros & Cons, G2 - Epic Reviews 2026: Details, Pricing, & Features
Last updated: 2026-08-05
Ratings & Reviews
Rate 4DMedical (Imbio)
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for 4DMedical (Imbio).
